Detalles de la búsqueda
1.
Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.
J Clin Immunol
; 43(6): 1414-1425, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37160610
2.
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Clin Exp Immunol
; 210(2): 91-103, 2022 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208448
3.
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies.
Front Immunol
; 13: 1110388, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36605207
4.
Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]).
Immunotherapy
; 13(10): 813-824, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33955240
5.
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Front Immunol
; 10: 40, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30778345
Resultados
1 -
5
de 5
1
Próxima >
>>